Abstract:Objective The reviewed literature supports a treatment regimen for primary central nervous system lymphoma (PCNSL) that includes induction chemotherapy, followed by one consolidation therapy. High-dose chemotherapy supported by autologous stem-cell transplantation (ASCT) is the most studied option, but its effects are controversial. The aim of this study was to evaluate the efficacy and safety of ASCT for newly diagnosed PCNSL by means of a meta-analysis. Methods The PubMed, Embase, and Cochrane Library databases were systematically searched for studies published until May 20, 2021. Included studies were prospective studies of patients with newly diagnosed PCNSL treated with ASCT. The pooled rates and 95% confidence intervals (CIs) were determined for all outcomes. Subgroup analysis was conducted to compare the relative risk (RR) with 95% CIs for the complete remission (CR) rate and the hazard ratios (HRs) with 95% CIs for progression-free survival (PFS) and overall survival (OS). Results Thirteen prospective studies including 348 patients were analyzed. The pooled CR rate, overall response rate, and relapse rate were 80% (95% CI, 71–88%, I 2 = 67.06%, p = 0.00), 95% (95% CI, 87–100%, I 2 = 73.65%, p = 0.00), and 19% (95% CI, 15–24%, I 2 = 76.18%, p = 0.00), respectively. The pooled 2- and 5-year PFS and OS rates were 74% (95% CI, 68–80%, I 2 = 3.90%), 65% (95% CI, 51–77%, I 2 = 74.61%), 80% (95% CI, 72–88%, I 2 = 57.54%), and 69% (95% CI, 53–83%, I 2 = 83.89%), respectively. Hematological toxicity and infections were more common adverse events above grade 3. The pooled treatment-related mortality was 3% (95% CI, 1–6%, I 2 = 28.18%, p = 0.16). In the group analysis of ASCT compared with whole-brain radiotherapy, there were no significant differences in the CR rate (RR, 1.00, 95% CI, 0.88–1.14, p = 0.971), relapse rate (RR, 0.44, 95% CI, 0.06–3.10, p = 0.408), PFS (HR, 1.28, 95% CI, 0.81–2.01, p = 0.29), or OS (HR, 1.62, 95% CI, 0.97–2.69, p = 0.06). Cognitive functions were preserved or improved after ASCT. Conclusions ASCT is a feasible approach for consolidation with good tolerability for newly diagnosed PCNSL patients. High-quality randomized controlled trials are still needed to confirm the effects of ASCT. Systematic Review Registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42021268422.

Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost–benefit analysis

Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.

Myeloablative Versus Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101

High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom

Evolving consolidation patterns and outcomes for a large cohort of primary CNS lymphoma patients

Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China

Primary Central Nervous System Lymphoma, Treatment Outcomes - 10 Year Experience. Single Center Study

Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review

A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime

Survival outcomes and treatment experience of 124 patients with primary central nervous system lymphoma

Consolidation Regimen and Cerebral Atrophy in Patients with Primary Central Nervous System Lymphoma

Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies

Characterizing second line and beyond therapies for primary central nervous system lymphomas

High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors

Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020

Challenges in the management of primary central nervous system lymphoma

PB1811 A SINGLE ARM MULTICENTENNIAL CLINICAL STUDY IN THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA(PCNSL) WITH ALTERNATIVE CHEMOTHERAPY SEQUENT WITH AUTOLOGOUS TRANSPLANTATION

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance

Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis

Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma